Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McMaster University

$105,000.00

The Identification of the Amino Acids on Platelet Factor 4 That Bind Pathogenic Antibodies in Heparin-Induced Thrombocytopenia

EF 2017-18

Résumé
At least 30% of patients admitted into the hospital will be exposed to the common anticoagulant, heparin. 1-3% of these patients develop heparin-induced thrombocytopenia (HIT): an adverse drug reaction that can lead to amputations, strokes, and death. HIT remains a major cause of morbidity and mortality in patients receiving heparin if not diagnosed and treated in a timely manner. Therefore, there is a need to develop a rapid and accurate diagnostic test for HIT that will improve the management of HIT patients. HIT occurs when patients who receive heparin form antibodies which subsequently results in an immune response but most of the antibodies formed in patients do not cause HIT. HIT only develops in those patients who produce immune complexes that cause intense platelet activation, low platelet counts, and clotting. Current rapid and available diagnostics tools cannot distinguish between antibodies that can or cannot cause the disease. Prompt diagnosis and treatments mitigate the life-threatening complications of HIT. However, the presence of these clinically insignificant antibodies greatly increases the over-diagnosis and mistreatment of patients thought to have the disease, increasing the risk of bleeding. To improve HIT diagnosis, we will identify the molecular differences between the antibodies that cause HIT and those that do not. This will be done by developing mutants of the protein that binds HIT antibodies and test the ability to incite platelet activation. From this, we can develop a new diagnostic assay that will be able to dictate whether the antibodies found in patients are specific for HIT. This development of a rapid and accurate diagnostic test will improve the management of HIT patients.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
383339
Name
Huynh Angela
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Identification of the Amino Acids on Platelet Factor 4 That Bind Pathogenic Antibodies in Heparin-Induced Thrombocytopenia
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Antibody Epitope Mapping; Heparin-Induced Thrombocytopenia; Platelet Activation; Platelet Factor 4
Abstract
At least 30% of patients admitted into the hospital will be exposed to the common anticoagulant, heparin. 1-3% of these patients develop heparin-induced thrombocytopenia (HIT): an adverse drug reaction that can lead to amputations, strokes, and death. HIT remains a major cause of morbidity and mortality in patients receiving heparin if not diagnosed and treated in a timely manner. Therefore, there is a need to develop a rapid and accurate diagnostic test for HIT that will improve the management of HIT patients. HIT occurs when patients who receive heparin form antibodies which subsequently results in an immune response but most of the antibodies formed in patients do not cause HIT. HIT only develops in those patients who produce immune complexes that cause intense platelet activation, low platelet counts, and clotting. Current rapid and available diagnostics tools cannot distinguish between antibodies that can or cannot cause the disease. Prompt diagnosis and treatments mitigate the life-threatening complications of HIT. However, the presence of these clinically insignificant antibodies greatly increases the over-diagnosis and mistreatment of patients thought to have the disease, increasing the risk of bleeding. To improve HIT diagnosis, we will identify the molecular differences between the antibodies that cause HIT and those that do not. This will be done by developing mutants of the protein that binds HIT antibodies and test the ability to incite platelet activation. From this, we can develop a new diagnostic assay that will be able to dictate whether the antibodies found in patients are specific for HIT. This development of a rapid and accurate diagnostic test will improve the management of HIT patients.
Competitiondate
201710
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Huynh, Angela
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~